The history of the hepatitis B vaccine has been marked by controversies, from the ‘Australia antigen’ to the ‘Pediatric ...

Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases. The company is dedicated to educating ...

Switching to a long-acting cabotegravir/rilpivirine antiretroviral regimen may be safe for patients with HIV who have prior hepatitis B virus exposure, a real-world study shows.

HBV coinfection with acute exacerbation was associated with significantly worse survival outcomes in pediatric T-ALL.

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in blood ...

A greater percentage of patients treated with tenofovir alafenamide achieved HBV DNA levels below 20 IU/mL at 24 weeks compared with placebo. The Food and Drug Administration (FDA) has expanded the ...

HepatitisB paper The approval was supported by data from a phase 2 trial that included 70 patients aged 12 to less than 18 years with chronic HBV infection. The Food and Drug Administration (FDA) has ...

The influenza season marks the beginning of a time of illness, sometimes serious or even fatal, in much of the world. For this reason, flu shots are recommended, especially for individuals with ...

Globally, the hepatitis B virus is a major cause of mortality from infectious diseases. Around 250 million people suffer from chronic HBV infections, with the virus being responsible for over one ...

The chronic hepatitis D virus market is expected to grow steadily, driven by a relatively small pipeline of emerging therapies. Leading candidates, such as Brelovitug from Bluejay Therapeutics and the ...